ST-Elevation Myocardial Infarction Associated With Infective Endocarditis.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 04 2019
Historique:
received: 08 11 2018
revised: 02 01 2019
accepted: 07 01 2019
pubmed: 21 3 2019
medline: 9 1 2020
entrez: 21 3 2019
Statut: ppublish

Résumé

ST-elevation myocardial infarction (STEMI) as a complication of infective endocarditis (IE) is a rarely reported entity. No clear guidelines exist with regards to the management of this medical emergency. We sought to systematically review the clinical presentation and management of this condition. We searched relevant articles on STEMI associated with IE and extracted data on demographic variables, key clinical characteristics upon presentation, treatment strategies, and clinical outcomes. We identified 100 patients from 95 articles. The mean age at presentation was 53 ± 17 years with male preponderance (n = 63, 63%, p = 0.01). Most patients (63 of 100, 63%) presented with STEMI as their first manifestation of IE, with others occurring at 15 ± 17 days after diagnosis of IE. Findings that suggested possible septic emboli were not consistently present, including history of prosthetic valve placement (15%), presence of other embolic disease (27%), fever (42%) increased leukocyte count (80%), and presence of murmur (88%). Atherosclerotic disease was absent in 95% on cardiac catheterization. Eleven patients receiving tissue plasminogen activator fared poorly, with 9 major bleeds; balloon angioplasty was successful in 56% (9 of 16 cases), aspiration thombectomy in 68% (21 of 31 cases), and coronary stenting in 81% (14 of 16 cases). The 30-day mortality was 43%. In conclusion, patients with STEMI in the face of recent IE, new precordial murmur, fever, increased leukocyte count or other embolic events, septic emboli should be considered as a cause for STEMI. Best practices for management are not known, but thrombolytics appear to carry significant bleeding and embolic risks.

Identifiants

pubmed: 30890259
pii: S0002-9149(19)30125-0
doi: 10.1016/j.amjcard.2019.01.033
pii:
doi:

Types de publication

Journal Article Meta-Analysis Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1239-1243

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Salik Nazir (S)

Department of Internal Medicine, Reading Hospital-Tower Health System, West Reading, Pennsylvania. Electronic address: saliknazir133@gmail.com.

Eric Elgin (E)

Division of Cardiology, Reading Hospital-Tower Health System, West Reading, Pennsylvania.

Richard Loynd (R)

Department of Internal Medicine, Reading Hospital-Tower Health System, West Reading, Pennsylvania.

Mumtaz Zaman (M)

Division of Pulmonary and Critical Care, Reading Hospital-Tower Health System, West Reading, Pennsylvania.

Anthony Donato (A)

Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH